Medical Journals

Efficient Production of Bioactive Insulin from Human Epidermal Keratinocytes and Tissue-engineered Skin Substitutes: Implications for Treatment of Diabetes.

Authors:
  • Lei Pedro
  • Ogunade Adebimpe
  • Kirkwood Keith L
  • Laychock Suzanne G
  • Andreadis Stelios T

From: Bioengineering Laboratory, Department of Chemical and Biological Engineering, University at Buffalo, The State University of New York, Amherst, New York 14260, USA.

Tissue engineering

  • Publish Date: Aug 2007
  • ISSN: 1076-3279
  • Volume: 13
  • Issue: 8
  • Pages: 2119-31
  • Medium: Print
  • Language: English
  • Citation (JAMA): Lei Pedro, Ogunade Adebimpe, Kirkwood Keith L, et al. Efficient Production of Bioactive Insulin from Human Epidermal Keratinocytes and Tissue-engineered Skin Substitutes: Implications for Treatment of Diabetes.. Tissue Eng. Aug 2007;13:2119-31

Abstract

Despite many years of research, daily insulin injections remain the gold standard for diabetes treatment. Gene therapy may provide an alternative strategy by imparting the ability to secrete insulin from an ectopic site. The epidermis is a self-renewing tissue that is easily accessible and can provide large numbers of autologous cells to generate insulin-secreting skin substitutes. Here we used a recombinant retrovirus to modify human epidermal keratinocytes with a gene encoding for human proinsulin containing the furin recognition sequences at the A-C and B-C junctions. Keratinocytes were able to process proinsulin and secrete active insulin that promoted glucose uptake. Primary epidermal cells produced higher amounts of insulin than cell lines, suggesting that insulin secretion may depend on the physiological state of the producer cells. Modified cells maintained the ability to stratify into 3-dimensional skin equivalents that expressed insulin at the basal and suprabasal layers. Modifications at the furin recognition sites did not improve proinsulin processing, but a single amino acid substitution in the proinsulin B chain enhanced C-peptide secretion from cultured cells and bioengineered skin substitutes 10- and 28-fold, respectively. These results suggest that gene-modified bioengineered skin may provide an alternative means of insulin delivery for treatment of diabetes.

Mesh Headings (Keywords): 3T3-L1 Cells, Animals, Cell Line, Cell Line, Tumor, Cells, Cultured, Diabetes Mellitus, Gene Therapy, Humans, Insulin, Keratinocytes, Mice, Proinsulin, Skin, Artificial, Transduction, Genetic


Check for Full Text / PubMed Unique Identifier (PMID): 17518716


This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.


Advertisements

About | Privacy Policy | Business Solutions | Advertise | Contact | Add Healia to your site

©2012. Healia / Meredith Corporation  

Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All content on this Web site, including medical opinion and any other health-related information, is for informational purposes only and should not be used for a specific diagnosis or individual treatment plan for any situation. Use of this site and the information contained herein does not create a doctor-patient relationship. Always seek the direct advice of your doctor in connection with any questions or issues you may have regarding your own health or the health of others.